Infirmière Parler à Patient
First-In-Class
Therapeutics for
Poorly Sensitive Cancers

Our Company

BiPER Therapeutics is a preclinical-stage biotech company founded in 2021 to develop and commercialize novel therapeutics. We are developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer through the modulation of the endoplasmic reticulum stress.

New Therapeutic Solutions 

False colour transmission electron microscope micrograph showing a continuity between the

Resistance to standard chemotherapeutic treatments and poor responses to immune-based therapies represent major challenges in cancer treatment as many patients respond poorly or not at all to currently available treatment options.

BiPER Therapeutics aims to bridge this important treatment gap by developing novel therapeutic solutions based on these core principles: 

 

  • Targeting the global metabolism of cancer cells
     

  • Modulating the Endoplasmic Reticulum Stress (ER stress) : 
    a pathway involved in cancer treatment resistance
     

  • Discovery and development of our BPR series of First-In-Class small molecules selectively targeting BiP/GRP78 :
    a key chaperone protein involved in ER stress
     

  • Selectively activating cell death in cancer cells and increasing recognition by the immune system in treatment-resistant as well as sensitive cancers
     

Founders & Executive Team

Photo Pro_Mehdi_CHELBI Mehdi_2018-08-06.jpg

Mehdi Chelbi

MSc


Co-Founder & CEO

  • Grey LinkedIn Icon

Biotech - Pharma - CRO
Corporate & Drug Development Experience 

Photo Zaki HQ_edited.jpg

Zaki Sellam

Msc MBA


Co-Founder
& Executive Chairman

  • Grey LinkedIn Icon

Entrepreneurship & Drug Development Expertise

Photo Stephane HQ.JPG

Stephane Rocchi

PhD - Research Director Inserm

Co-Founder 

 

  • Grey LinkedIn Icon

Expertise in Biology and Translational Research in Oncology @ C3M

Photo Rachid HQ.jpg
  • Grey LinkedIn Icon

Expertise in Medicinal Chemistry, Drug Design and Pharmacology @ICN

Photo Cyril HQ.jpg

Cyril Ronco

PhD - MC - HDR


Co-Founder 

 

  • Grey LinkedIn Icon

Expertise in Medicinal Chemistry, Drug Design and Pharmacology @ICN

Rachid Benhida

PhD - Research Director CNRS

Co-Founder 

 

Pipeline

Pipeline BiPER TX_2021-10-12.png
Empreinte Logo.png

Will attend several conferences in 2022 stay tuned

Ecosystem & Partners

BPI logo.png
Inserm Transfert Logo.png
Region Grand Est.png
Logo Semia.png
MATWIN Logo.png
C3M Logo.jfif
ICN Logo.png
Logo Canceropôle_PACA_DEF.jpg
BioValley.png
BiPER Logo on Blue.png

11 Rue de l'Académie

67000 Strasbourg

France

 

contact@biper-tx.com